

**ChemBioHepatox: Multimodal Integrating Chemical Structure and
Biological Fingerprint for Robust and Interpretable Hepatotoxicity
Prediction**

Yingqing Shou^{1,2}, Yongbao Fang^{2,4}, Yu Ma², Yuan Chi², Jingzhi Yao², Jie Xu⁵, YongFeng Deng^{*1}, Bo Peng^{*3}, Mingliang Fang^{*2}

*Corresponding authors. Email: yfdeng@seu.edu.cn, pengbo@pku.edu.cn and mlfang@fudan.edu.cn

¹ Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China; ² Department of Environmental Science and Engineering, Fudan University, Shanghai 200438, China; ³ SKL-ESPC and College of Environmental Sciences and Engineering, Center for Environment and Health, Peking University, Beijing 100871, China; ⁴ Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China; ⁵ Fudan University, Shanghai 200438, China.


Table of Contents:

| | |
|---|--------|
| Supplementary Methods Identification of a comprehensive hepatotoxicity assay response spectrum - Step 3: Mechanism Mapping | S3 |
| Supplementary Fig. 1 Chemical classification and assay response analysis of hepatotoxic compounds. | S4 |
| Supplementary Fig. 2 Data characteristics and model performance metrics. | S5 |
| Supplementary Fig. 3 Extended activity cliff analysis demonstrating structure-mechanism complementarity. | S6 |
| Supplementary Fig. 4 ChemBioHepatox attention mechanism visualization for Pair B. | S7 |
| Supplementary Fig. 5 Cell viability assays for model-predicted hepatotoxic compounds. | S8 |
| Supplementary Table 1. Characteristics of the 19 key assays in the hepatotoxicity response spectrum. | S9-S12 |
| Supplementary Table 2. Characteristics of the 19 key assays in the hepatotoxicity response spectrum. | S13 |
| Supplementary Table 3. Predicted hepatotoxicity of synthetic food colorants and supporting evidence. | S14 |


Supplementary Methods

Identification of a comprehensive hepatotoxicity assay response spectrum - Step 3: Mechanism Mapping. To establish a comprehensive and systematic hepatotoxicity assay response spectrum, we further processed the 38 significantly correlated assays by eliminating redundant assays and phenotypic indicators while prioritizing molecular mechanism level assays. This refinement process involved eliminating duplicate significance assays (retaining ER-beta Agon qHTS: Summary while removing ER-beta Agon qHTS), excluding phenotypic indicators (SGOT, SGPT) in favor of mechanism-level assays, and removing weakly correlated or hepatotoxicity-irrelevant assays (such as D3 Receptor Agon qHTS). This process yielded 17 key assays. We next mapped these assays to the established comprehensive framework of hepatotoxicity mechanisms, which systematically categorizes hepatotoxicity into 12 fundamental mechanisms. Upon mapping our assays to this framework, we identified coverage gaps in two critical mechanisms: transport function disruption and cytoskeletal disruption. To achieve complete mechanistic coverage, we strategically incorporated two additional assays—MDR-1 (transmembrane transport) and ER stress (cytoskeletal function)—resulting in a final panel of 19 key assays that collectively span all 12 fundamental hepatotoxicity mechanisms.


Supplementary Figures




Supplementary Fig. 1 | Chemical classification and assay response analysis of hepatotoxic compounds. **a** Distribution of DILI-positive (red, n=768) and DILI-negative (blue, n=511) compounds across different chemical classes according to ClassyFire taxonomic system. Percentages indicate proportion within each class. **b** Visualization of the drug-assay response matrix (1170 × 1510) showing distribution of positive (red), negative (blue), and missing values (white). Matrix exhibits 86% sparsity. **c** List of 38 statistically significant hepatotoxicity-associated assays identified through dual statistical screening approach. **d** Heatmap of Pearson correlation coefficients between the 19 key assays in the final panel. Color intensity indicates correlation strength from 0.0 (blue) to 1.0 (red), with gray cells representing insufficient data for correlation calculation.



Supplementary Fig. 2 | Data characteristics and model performance metrics. a Percentage distribution of missing values and class labels across the 19 key assays. Blue segments represent missing data, green segments represent negative class (0) samples, and orange segments represent positive class (1) samples. **b** Comparison between empirical (solid blue line with circles) and theoretical (dashed gray line) entropy distributions across prediction probability values. **c** Receiver operating characteristic (ROC) curve for the standardized SMILES representation approach with area under curve (AUC), precision, and recall values indicated in the legend.




Supplementary Fig. 3 | Extended activity cliff analysis demonstrating structure-mechanism complementarity. **a** Molecular structures of the remaining 10 activity cliff pairs (Pairs E - N) not shown in the main text, with CID numbers, toxicity labels, and prediction probabilities. **b** Assay response profiles for 10 additional activity cliff pairs (Pairs E-N), showing response values (0.0-1.0) across 19 key assays. Blue lines with circular markers represent non-hepatotoxic compounds, while pink lines with circular markers represent hepatotoxic compounds. Structural similarity and assay similarity scores are provided at the bottom of each panel.




Supplementary Fig. 4 | ChemBioHepatox attention mechanism visualization for Pair B highlighting the differential attention distribution patterns between structurally similar molecules with opposite toxicity labels (B+: non-hepatotoxic, Label 0; B-: hepatotoxic, Label 1). Color intensity represents attention weight, with warmer colors indicating regions of higher attention by the model.

a.



b.



Supplementary Fig. 5 | Cell viability assays for model-predicted hepatotoxic compounds.

a Bar graph showing dose-dependent cytotoxicity of chlorothalonil (dark blue) and thiophanate-methyl (light blue) in HepG2 cells after 24-hour exposure. Cell viability is expressed as percentage of control (0 μM), with significant decreases observed at all tested concentrations for chlorothalonil and at concentrations ≥ 60 μM for thiophanate-methyl ($***p < 0.001$). **b** Bar graph showing the dose-dependent effects of curcumin on HepG2 cell viability after 24-hour exposure. Curcumin maintains cell viability at lower concentrations (≤ 20 μM) but exhibits significant cytotoxicity at higher concentrations (50 μM and 100 μM) ($***p < 0.001$).

Supplementary Table

Supplementary Table 1. Characteristics of the 19 key assays in the hepatotoxicity response spectrum

| Assay Name | Abbreviation | PubChem AID | Protein Target | Corresponding KC* |
|--|-------------------|-------------|---|-------------------|
| Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay: Summary | Caspase-3/7 HepG2 | 1347034 | caspase-3; caspase 7; apoptosis-related cysteine protease | KC2; KC3 |
| Cytochrome P450 Family 1 Subfamily A Member 2 (CYP1A2) small molecule antagonists: luciferase reporter qHTS assay | CYP1A2 Antag | 1671199 | cytochrome P450; family 1; subfamily A; polypeptide 2 | KC1; KC12 |
| Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) small molecule antagonists: luciferase reporter qHTS assay | CYP2C19 Antag | 1671197 | cytochrome P450; family 2; subfamily C; polypeptide 19 | KC1; KC12 |
| Cytochrome P450 Family 2 Subfamily C Member 9 (CYP2C9) small molecule antagonists: luciferase reporter qHTS assay | CYP2C9 Antag | 1671198 | cytochrome P450 family 2 subfamily C polypeptide 9 | KC1; KC12 |
| Cytochrome P450 Family 3 Subfamily A Member 4 (CYP3A4) small molecule antagonists: luciferase reporter qHTS assay | CYP3A4 Antag | 1671201 | cytochrome P450 family 3 subfamily A polypeptide 4 | KC1; KC12 |
| Cytochrome P450 family 3 subfamily A member 7 (CYP3A7) small molecule antagonists: luciferase cell-based qHTS | CYP3A7 Antag | 1963596 | cytochrome P450 3A7 [Homo sapiens] | KC1; KC12 |

assay

| | | | | |
|--|-----------------------|---------|---|----------------|
| qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary | ARE Agon | 743219 | nuclear factor erythroid 2-related factor 2 isoform 1 | KC5; KC8 |
| qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability | Mito Membrane Disrupt | 720634 | NA | KC2; KC5; KC7 |
| qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen | ER Stress | 1159517 | NA | KC2; KC8; KC10 |
| qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary | ER-beta Agon | 1259394 | estrogen receptor 2 (ER beta) | KC3; KC12 |
| qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary | PPARg Agon | 743140 | peroxisome proliferator activated receptor gamma | KC3; KC12 |
| qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway | RAR Agon | 1159553 | retinoic acid nuclear receptor alpha variant 1 | KC3; KC9 |
| qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library | ERR Antag | 1224848 | estrogen-related nuclear receptor alpha | KC1; KC12 |

| | | | | |
|---|-------------|--------|--|-----------|
| qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary | GR Antag | 720725 | glucocorticoid receptor [Homo sapiens] | KC6; KC12 |
| qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway | PPARd Antag | 743215 | peroxisome proliferator-activated receptor delta | KC3; KC12 |
| qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary | PPARg Antag | 743199 | peroxisome proliferator activated receptor gamma | KC8; KC12 |
| qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary | TR Antag | 743167 | thyroid hormone receptor beta isoform 2 | KC1; KC12 |
| MDR-1 | MDR-1 | 377 | ATP-dependent translocase ABCB1 isoform 2 | KC4; KC7 |
| qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase) | HPGD Inhib | 894 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | KC6; KC11 |

* KC (Key Characteristics) of Hepatotoxicants:

KC1. Is reactive and/or is metabolized (bioactivated) to reactive moieties

KC2. Causes death (apoptosis and/or necrosis) of liver cells

KC3. Affects liver cell proliferation and/or tissue regeneration

KC4. Disrupts transport function

KC5. Induces oxidative stress

- KC6. Triggers immune-mediated responses in liver
- KC7. Causes mitochondrial dysfunction
- KC8. Activates stress signaling pathways
- KC9. Causes cholestasis
- KC10. Disrupts cellular cytoskeleton
- KC11. Causes liver fibrosis
- KC12. Disrupts liver metabolism, including of lipids and proteins

Supplementary Table 2. Characteristics of the 19 key assays in the hepatotoxicity response spectrum

| Pair ID | Assay Similarity | Structural Similarity | Pair ID | Assay Similarity | Structural Similarity |
|----------------|------------------|-----------------------|----------------|------------------|-----------------------|
| Pair 1 | 1.00 | 0.72 | Pair 20 | 0.98 | 0.53 |
| Pair 2 | 1.00 | 0.94 | Pair 21 | 1.00 | 0.42 |
| Pair 3 | 1.00 | 0.29 | Pair 22 | 1.00 | 0.75 |
| Pair 4 | 1.00 | 0.36 | Pair 23 | 0.69 | 0.15 |
| Pair 5 | 1.00 | 0.36 | Pair 24 | 1.00 | 0.62 |
| Pair 6 | 0.35 | 0.13 | Pair 25 | 0.99 | 0.61 |
| Pair 7 | 1.00 | 0.47 | Pair 26 | 1.00 | 0.66 |
| Pair 8 | 1.00 | 0.86 | Pair 27 | 0.98 | 0.65 |
| Pair 9 | 1.00 | 0.89 | Pair 28 | 1.00 | 0.26 |
| Pair 10 | 0.12 | 0.57 | Pair 29 | 0.54 | 0.77 |
| Pair 11 | 1.00 | 0.23 | Pair 30 | 1.00 | 0.70 |
| Pair 12 | 1.00 | 0.64 | Pair 31 | 0.67 | 0.15 |
| Pair 13 | 0.68 | 0.13 | Pair 32 | 0.76 | 0.82 |
| Pair 14 | 1.00 | 0.93 | Pair 33 | 1.00 | 0.80 |
| Pair 15 | 1.00 | 0.48 | Pair 34 | 0.10 | 0.59 |
| Pair 16 | 1.00 | 0.54 | Pair 35 | 0.91 | 0.76 |
| Pair 17 | 1.00 | 0.51 | Pair 36 | 1.00 | 0.88 |
| Pair 18 | 1.00 | 0.64 | Pair 37 | 0.85 | 0.56 |
| Pair 19 | 1.00 | 0.55 | Pair 38 | 0.07 | 0.27 |

Supplementary Table 3. Predicted hepatotoxicity of synthetic food colorants and supporting evidence

| Food Colorant | E Number | Predicted Probability | Key Findings from Literature | Reference |
|------------------------|-----------------|------------------------------|--|------------------|
| Sunset Yellow | E110 | 0.99 | Hepatocyte damage; elevated liver enzymes; altered antioxidant systems | 27 |
| Carmoisine | E122 | 1.00 | Oxidative stress; elevated liver enzymes; histopathological changes | 28 |
| Allura Red | E129 | 0.99 | Oxidative stress; inflammatory responses; dose-dependent effects | 29 |
| Tartrazine | E102 | 1.00 | Increased oxidative markers; altered liver function | 30 |
| Curcumin | E100 | 0.95 | Dose dual effect: hepatoprotective at low doses, hepatotoxic at high doses | 31 |
| Cochineal Red A | E124 | 0.96 | Mitochondrial dysfunction; increased oxidative stress | 32 |
| Brilliant Blue | E133 | 1.00 | Liver tissue accumulation; vacuolation, swelling, necrosis and pyknosis of liver cells | 33 |